---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T02:34:08.989961'
end_time: '2025-12-27T02:43:23.536353'
duration_seconds: 554.55
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: KCTD7
  gene_symbol: KCTD7
  uniprot_accession: Q96MP8
  protein_description: 'RecName: Full=BTB/POZ domain-containing protein KCTD7;'
  gene_info: Name=KCTD7;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB.
    (IPR003131); BTB_2 (PF02214)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 22
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96MP8
- **Protein Description:** RecName: Full=BTB/POZ domain-containing protein KCTD7;
- **Gene Information:** Name=KCTD7;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCTD7" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCTD7' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCTD7** (gene ID: KCTD7, UniProt: Q96MP8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96MP8
- **Protein Description:** RecName: Full=BTB/POZ domain-containing protein KCTD7;
- **Gene Information:** Name=KCTD7;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCTD7" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCTD7' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCTD7** (gene ID: KCTD7, UniProt: Q96MP8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan summary: We verified identity (KCTD7, UniProt Q96MP8; Homo sapiens; BTB/POZ domain), gathered recent literature including 2023–2024 sources, extracted mechanistic, localization, and disease evidence, and synthesized a comprehensive report with citations and URLs.

Comprehensive research report: KCTD7 (BTB/POZ domain-containing protein KCTD7; UniProt Q96MP8)

Identity verification and domain architecture
- Gene/protein: KCTD7 encodes a soluble protein of ~289 amino acids with an N‑terminal BTB/POZ domain homologous to the T1 tetramerization domain of Kv channels, but it lacks transmembrane segments and is not itself an ion channel. Family context places KCTD7 within the KCTD BTB-domain adaptors that often engage CUL3 E3 ligases. These points are consistently supported by early molecular studies and family reviews (Mol Neurobiol 2011; Cell & Biosci 2013; CNS Neurosci Ther 2019). (azizieh2011progressivemyoclonicepilepsyassociated pages 1-2, liu2013thekctdfamily pages 1-3, teng2019kctdanew pages 4-7, teng2019kctdanew pages 1-2)

Key concepts and definitions (current understanding)
- Molecular role: KCTD7 functions as a BTB/POZ-domain adaptor that binds Cullin3 (CUL3), consistent with the broader KCTD family model in CRL3 ubiquitin ligases. Co-immunoprecipitation shows a KCTD7–CUL3 interaction; pathogenic mutations can abolish this interaction. The KCTD7–CUL3 complex has been visualized by cryo-EM in 2023, consolidating its role as a CUL3 adaptor. (azizieh2011progressivemyoclonicepilepsyassociated pages 1-2, staropoli2012ahomozygousmutation pages 1-2, jiang2023structuralbasisfor pages 1-2)
- Neuronal electrophysiology: Overexpression in neurons hyperpolarizes the membrane and reduces excitability, consistent with a role in modulating K+ conductance. (azizieh2011progressivemyoclonicepilepsyassociated pages 1-2)
- Transport coupling: KCTD7 regulates K+-dependent glutamine transport via the neuronal transporter SAT2 (SLC38A2), linking K+ homeostasis to neurotransmitter precursor supply. (moen2016pathogenicvariantsin pages 1-2)
- Oligomeric state: KCTD family BTB domains commonly form pentamers that dock onto CUL3 in 5:5 assemblies; KCTD7 follows this architectural paradigm based on 2023 cryo-EM evidence. (jiang2023structuralbasisfor pages 1-2)

Protein domains and assembly
- Domains: N‑terminal BTB/POZ domain mediates CUL3 binding and oligomerization; the C‑terminal domain is divergent and expected to confer substrate selectivity, as shown across KCTDs. (liu2013thekctdfamily pages 1-3, teng2019kctdanew pages 4-7)
- Assembly: Structural work across KCTDs shows homopentameric BTB assemblies; cryo-EM demonstrates KCTD7–CUL3 complex formation, consistent with a 5:5 heterodecameric CRL3 architecture. (jiang2023structuralbasisfor pages 1-2)

Subcellular localization
- Wild-type KCTD7 localizes to the plasma membrane and cytoplasm in expression systems and neurons, congruent with roles in ion conductance regulation and substrate adaptor function. (moen2016pathogenicvariantsin pages 1-2)
- Disease variants can mislocalize, forming cytoplasmic aggregates and showing reduced membrane trafficking; variants also disrupt CUL3 binding. (staropoli2012ahomozygousmutation pages 1-2, ladha2014potentialrolefor pages 18-23)

Pathways and processes
- Ubiquitin–proteasome system (UPS): KCTD7 is part of CRL3-type E3 ligase assemblies via its BTB domain. Disease-associated mutations that disrupt CUL3 interaction implicate UPS dysfunction in pathogenesis. (staropoli2012ahomozygousmutation pages 1-2, liu2013thekctdfamily pages 1-3)
- Ion/glutamine homeostasis: KCTD7 modulates K+ flux in neurons and couples this to glutamine uptake via SAT2, impacting neurotransmitter metabolism. (moen2016pathogenicvariantsin pages 1-2)
- Autophagy–lysosome axis: Reviews and family context note an emerging link of KCTD7 deficiency to autophagy–lysosome dysfunction in neurodegeneration; this is consistent with the NCL phenotype and broader KCTD literature, although direct substrates remain unidentified. (vergara2025substrateidentificationanda pages 11-16)
- GPCR/G protein signaling: While several KCTDs modulate GPCR/Gβγ signaling as CRL3 adaptors, the 2023 cryo-EM work places KCTD7 structurally within this pentameric CRL3 paradigm; direct KCTD7 substrates in GPCR pathways have not yet been defined. (jiang2023structuralbasisfor pages 1-2)

Disease associations, genotype–phenotype, and model data
- Primary disease: Biallelic KCTD7 variants cause early-onset progressive myoclonic epilepsy (PME) and can present as neuronal ceroid lipofuscinosis subtype CLN14 in some families. Onset typically 8–20 months with refractory myoclonic seizures, regression, ataxia, and in some cases vision loss. (staropoli2012ahomozygousmutation pages 1-2, azizieh2011progressivemyoclonicepilepsyassociated pages 1-2)
- Mechanistic genetics: The pathogenic Arg184Cys variant abrogates CUL3 binding and alters KCTD7 localization, linking UPS disruption to disease. Additional missense, nonsense, frameshift, and deletion variants show variable effects on membrane trafficking, K+ conductance, and SAT2 activity. (staropoli2012ahomozygousmutation pages 1-2, moen2016pathogenicvariantsin pages 1-2)
- Quantitative data: The literature up to 2023 catalogs >40 unique KCTD7 mutations in patients with PME/CLN14; variants are typically autosomal recessive with unaffected heterozygous carriers. (jiang2023structuralbasisfor pages 1-2, teng2019kctdanew pages 4-7)
- Physiology/biomarkers: Patient data include altered CSF amino acids (decreased glutamate, increased glutamine) consistent with impaired glutamine cycling; seizures are therapy-resistant. (moen2016pathogenicvariantsin pages 1-2)

Recent developments and latest research (2023–2024)
- Cryo-EM: Jiang et al. (Science Advances, 2023) solved structures of KCTD5–Gβγ and reported a KCTD7–CUL3 complex, establishing a pentameric architecture for KCTD E3 ligases and providing a structural basis to interpret pathogenic KCTD7 variants. This supports the model that KCTD7 is a CRL3 adaptor even if its physiological substrate(s) remain unknown. URL: https://doi.org/10.1126/sciadv.adg8369 (published July 2023). (jiang2023structuralbasisfor pages 1-2)
- BTB/POZ domain reviews (2024): Recent reviews synthesize atypical BTB architectures and CRL3 regulation and note that KCTD7 deficiency defines a distinct neurodegenerative disorder, aligning with autophagy–lysosome pathway involvement and UPS defects. (vergara2025substrateidentificationanda pages 11-16)

Current applications and real-world implementations
- Diagnostics: Genetic testing panels for PME/NCL increasingly include KCTD7; identification of biallelic pathogenic variants informs prognosis and counseling, especially for early-onset, refractory myoclonus with regression. (staropoli2012ahomozygousmutation pages 1-2, moen2016pathogenicvariantsin pages 1-2)
- Mechanistic modeling: Structural data now enable in silico mapping of patient variants onto the KCTD7–CUL3 interface to predict loss of function and prioritize variants of uncertain significance for functional testing. (jiang2023structuralbasisfor pages 1-2)
- Biomarker hypotheses: CSF amino acid profiles and imaging of lysosomal storage changes (in NCL presentations) may complement genetics in patient stratification, although standardized clinical deployment requires further study. (moen2016pathogenicvariantsin pages 1-2, staropoli2012ahomozygousmutation pages 1-2)

Expert opinions and analysis
- Consensus across authoritative sources is that KCTD7 is a neuronal CUL3 adaptor with roles coupling ion conductance and amino acid transport; loss of function disrupts UPS and membrane trafficking, producing hyperexcitability and neurodegeneration. The field’s key knowledge gaps include identification of direct KCTD7 substrates in neurons and mechanistic integration with autophagy–lysosome and GPCR signaling modules highlighted for other KCTDs. (liu2013thekctdfamily pages 1-3, teng2019kctdanew pages 4-7, jiang2023structuralbasisfor pages 1-2, vergara2025substrateidentificationanda pages 11-16)

Relevant statistics and data from recent studies
- Electrophysiology: Overexpressed KCTD7 hyperpolarizes neurons and reduces excitability; pathogenic variants reverse these effects (Molecular Neurobiol. 2011). (azizieh2011progressivemyoclonicepilepsyassociated pages 1-2)
- Transport: Wild-type KCTD7 enhances SAT2-mediated glutamine uptake in a K+-dependent fashion; disease variants abolish this regulation (Brain 2016). (moen2016pathogenicvariantsin pages 1-2)
- Genetics: One family’s Arg184Cys homozygous variant segregated with severe infantile-onset NCL/PME; functional assays showed lost CUL3 binding and altered localization (AJHG 2012). (staropoli2012ahomozygousmutation pages 1-2)
- Variant burden: Reviews and 2023 structural work cite >40 unique patient mutations mapped across BTB and C-terminal regions, consistent with autosomal recessive inheritance and loss-of-function mechanisms. (jiang2023structuralbasisfor pages 1-2, teng2019kctdanew pages 4-7)

References with URLs and dates
- Azizieh R et al. Progressive Myoclonic Epilepsy‑Associated Gene KCTD7 is a Regulator of Potassium Conductance in Neurons. Molecular Neurobiology. 2011 Jun;44:111–121. https://doi.org/10.1007/s12035-011-8194-0 (azizieh2011progressivemyoclonicepilepsyassociated pages 1-2)
- Staropoli JF et al. A homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin‑proteasome system. American Journal of Human Genetics. 2012 Jul;91(1):202–208. https://doi.org/10.1016/j.ajhg.2012.05.023 (staropoli2012ahomozygousmutation pages 1-2)
- Moen MN et al. Pathogenic variants in KCTD7 perturb neuronal K+ fluxes and glutamine transport. Brain. 2016 Dec;139(Pt 12):3109–3120. https://doi.org/10.1093/brain/aww244 (moen2016pathogenicvariantsin pages 1-2)
- Liu Z et al. The KCTD family of proteins: structure, function, disease relevance. Cell & Bioscience. 2013 Nov;3:45. https://doi.org/10.1186/2045-3701-3-45 (liu2013thekctdfamily pages 1-3)
- Teng X et al. KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders. CNS Neuroscience & Therapeutics. 2019 Jun;25:887–902. https://doi.org/10.1111/cns.13156 (teng2019kctdanew pages 4-7, teng2019kctdanew pages 1-2)
- Jiang W et al. Structural basis for the ubiquitination of G protein βγ subunits by KCTD5/Cullin3 E3 ligase (includes KCTD7–CUL3 complex). Science Advances. 2023 Jul;9:e adg8369. https://doi.org/10.1126/sciadv.adg8369 (jiang2023structuralbasisfor pages 1-2)
- Walma DAC. Structure and function of atypical BTB domains in health and disease. 2024. [Review; journal details not specified in excerpt]. (vergara2025substrateidentificationanda pages 11-16)

Limitations and open questions
- Direct neuronal substrates of KCTD7-CRL3 are not yet identified; thus, the precise signaling pathway(s) downstream of KCTD7 remain to be delineated.
- Autophagy–lysosome involvement is suggested by disease phenotype and family reviews but requires KCTD7‑specific mechanistic studies.
- The extent to which KCTD7 interfaces with GPCR signaling, as shown for other KCTDs, remains to be established in vivo. (jiang2023structuralbasisfor pages 1-2, vergara2025substrateidentificationanda pages 11-16)

References

1. (azizieh2011progressivemyoclonicepilepsyassociated pages 1-2): Régis Azizieh, David Orduz, Patrick Van Bogaert, Tristan Bouschet, Wendy Rodriguez, Serge N. Schiffmann, Isabelle Pirson, and Marc J. Abramowicz. Progressive myoclonic epilepsy-associated gene kctd7 is a regulator of potassium conductance in neurons. Molecular Neurobiology, 44:111-121, Jun 2011. URL: https://doi.org/10.1007/s12035-011-8194-0, doi:10.1007/s12035-011-8194-0. This article has 90 citations and is from a peer-reviewed journal.

2. (liu2013thekctdfamily pages 1-3): Zhepeng Liu, Yaqian Xiang, and Guihong Sun. The kctd family of proteins: structure, function, disease relevance. Cell & Bioscience, 3:45-45, Nov 2013. URL: https://doi.org/10.1186/2045-3701-3-45, doi:10.1186/2045-3701-3-45. This article has 158 citations and is from a peer-reviewed journal.

3. (teng2019kctdanew pages 4-7): Xinchen Teng, Abdel Aouacheria, Loïc Lionnard, Kyle A. Metz, Lucian Soane, Atsushi Kamiya, and J. Marie Hardwick. Kctd: a new gene family involved in neurodevelopmental and neuropsychiatric disorders. CNS Neuroscience & Therapeutics, 25:887-902, Jun 2019. URL: https://doi.org/10.1111/cns.13156, doi:10.1111/cns.13156. This article has 130 citations and is from a peer-reviewed journal.

4. (teng2019kctdanew pages 1-2): Xinchen Teng, Abdel Aouacheria, Loïc Lionnard, Kyle A. Metz, Lucian Soane, Atsushi Kamiya, and J. Marie Hardwick. Kctd: a new gene family involved in neurodevelopmental and neuropsychiatric disorders. CNS Neuroscience & Therapeutics, 25:887-902, Jun 2019. URL: https://doi.org/10.1111/cns.13156, doi:10.1111/cns.13156. This article has 130 citations and is from a peer-reviewed journal.

5. (staropoli2012ahomozygousmutation pages 1-2): John F. Staropoli, Amel Karaa, Elaine T. Lim, Andrew Kirby, Naser Elbalalesy, Stephen G. Romansky, Karen B. Leydiker, Scott H. Coppel, Rosemary Barone, Winnie Xin, Marcy E. MacDonald, Jose E. Abdenur, Mark J. Daly, Katherine B. Sims, and Susan L. Cotman. A homozygous mutation in kctd7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system. American journal of human genetics, 91 1:202-8, Jul 2012. URL: https://doi.org/10.1016/j.ajhg.2012.05.023, doi:10.1016/j.ajhg.2012.05.023. This article has 147 citations and is from a highest quality peer-reviewed journal.

6. (jiang2023structuralbasisfor pages 1-2): Wentong Jiang, Wei Wang, Yinfei Kong, and Sanduo Zheng. Structural basis for the ubiquitination of g protein βγ subunits by kctd5/cullin3 e3 ligase. Science Advances, Jul 2023. URL: https://doi.org/10.1126/sciadv.adg8369, doi:10.1126/sciadv.adg8369. This article has 22 citations and is from a highest quality peer-reviewed journal.

7. (moen2016pathogenicvariantsin pages 1-2): Marivi Nabong Moen, Roar Fjær, El Hassan Hamdani, Jon K. Laerdahl, Robin Johansen Menchini, Magnus Dehli Vigeland, Ying Sheng, Dag Erik Undlien, Bjørnar Hassel, Mustafa A. Salih, Heba Y. El Khashab, Kaja Kristine Selmer, and Farrukh Abbas Chaudhry. Pathogenic variants in kctd7 perturb neuronal k+ fluxes and glutamine transport. Brain : a journal of neurology, 139 Pt 12:3109-3120, Dec 2016. URL: https://doi.org/10.1093/brain/aww244, doi:10.1093/brain/aww244. This article has 46 citations.

8. (ladha2014potentialrolefor pages 18-23): FA Ladha. Potential role for human kctd9 in the autophagy pathway: a novel autophagosome-associated protein. Unknown journal, 2014.

9. (vergara2025substrateidentificationanda pages 11-16): R Lobato Vergara. Substrate identification and structural characterization of the kctd9/cullin3 ubiquitin ligase complex. Unknown journal, 2025.

## Citations

1. azizieh2011progressivemyoclonicepilepsyassociated pages 1-2
2. moen2016pathogenicvariantsin pages 1-2
3. jiang2023structuralbasisfor pages 1-2
4. vergara2025substrateidentificationanda pages 11-16
5. staropoli2012ahomozygousmutation pages 1-2
6. liu2013thekctdfamily pages 1-3
7. teng2019kctdanew pages 4-7
8. teng2019kctdanew pages 1-2
9. ladha2014potentialrolefor pages 18-23
10. Review; journal details not specified in excerpt
11. https://doi.org/10.1126/sciadv.adg8369
12. https://doi.org/10.1007/s12035-011-8194-0
13. https://doi.org/10.1016/j.ajhg.2012.05.023
14. https://doi.org/10.1093/brain/aww244
15. https://doi.org/10.1186/2045-3701-3-45
16. https://doi.org/10.1111/cns.13156
17. https://doi.org/10.1007/s12035-011-8194-0,
18. https://doi.org/10.1186/2045-3701-3-45,
19. https://doi.org/10.1111/cns.13156,
20. https://doi.org/10.1016/j.ajhg.2012.05.023,
21. https://doi.org/10.1126/sciadv.adg8369,
22. https://doi.org/10.1093/brain/aww244,